Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: February 1, 2023

Details for Patent: 7,919,483

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,919,483 protect, and when does it expire?

Patent 7,919,483 protects XIMINO and SOLODYN and is included in two NDAs.

This patent has twelve patent family members in nine countries.

Summary for Patent: 7,919,483

Title:	Method for the treatment of acne
Abstract:	A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.
Inventor(s):	Wortzman; Mitchell (Scottsdale, AZ), Plott; R. Todd (Briscoe, TX), Bhatia; Kuljit (Nesconset, NY), Patel; Bhiku (Chandler, AZ)
Assignee:	Medicis Pharmaceutical Corporation (Scottsdale, AZ)
Application Number:	11/166,817
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,919,483
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form; Delivery;

Drugs Protected by US Patent 7,919,483

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-001	Jul 11, 2012		RX	No	No	See Plans and Pricing	See Plans and Pricing				TREATMENT OF ACNE	See Plans and Pricing
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-003	Jul 11, 2012		RX	No	No	See Plans and Pricing	See Plans and Pricing				TREATMENT OF ACNE	See Plans and Pricing
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-005	Jul 11, 2012		RX	No	No	See Plans and Pricing	See Plans and Pricing				TREATMENT OF ACNE	See Plans and Pricing
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-001	May 8, 2006		DISCN	Yes	No	See Plans and Pricing	See Plans and Pricing				TREATMENT OF ACNE	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,919,483

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006262428	See Plans and Pricing
Canada	2613273	See Plans and Pricing
China	101208097	See Plans and Pricing
European Patent Office	1898925	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt

Boehringer Ingelheim

AstraZeneca

Moodys

Merck

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.